Expertise in
29
conditions

Dr. Neeharika S. Makani

Hematology | Oncology | Internal Medicine
603 7th St S, Ste 560, 
St. Petersburg, FL 
Accepting New Patients
Offers Telehealth
Expertise in
29
conditions
603 7th St S, Ste 560, 
St. Petersburg, FL 

Overview

Neeharika Makani is a Hematologist and an Oncologist practicing medicine in St. Petersburg, Florida.

Dr. Makani is highly rated in 29 conditions, according to our data. Her clinical expertise encompasses Anemia, Non-Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Ductal Adenocarcinoma, and Bone Marrow Aspiration.

Dr. Makani is board certified in AB Internal Medicine - Internal Medicine, AB Internal Medicine (Medical Oncology), and AB Internal Medicine (Hematology). She is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 7 clinical trials. Dr. Makani is currently accepting new patients.

Graduate Institution

Boston University

Residency

Ronald Reagan UCLA Medical Center - GME: Internal Medicine

Specialties

Hematology
Oncology
Internal Medicine

Licenses

Internal Medicine in FL

Board Certifications

AB Internal Medicine - Internal Medicine
AB Internal Medicine (Medical Oncology)
AB Internal Medicine (Hematology)

Fellowships

Beth Israel Deaconess Medical Center - GME: Hematology and Oncology

Hospital Affiliations

St Josephs Hospital
Orlando Health Bayfront Hospital
St Anthonys Hospital

Languages Spoken

English
Hindi

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

Comprehensive Hematology Oncology, LLC
603 7th St S, Ste 560, St. Petersburg, FL 33701
Other Locations
Comprehensive Hematology & Oncology LLC
5000 Park St N, Ste 1017, Saint Petersburg, FL 33709
Comprehensive Hematology & Oncology LLC
603 7th St S, Ste 560, Saint Petersburg, FL 33701
Comprehensive Hematology Oncology, Llc
603 7th St S, Ste 560, Saint Petersburg, FL 33701

Additional Areas of Focus

Dr. Makani has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Enrollment Status: Terminated
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: SY-1425+Azacitidine, Azacitidine
Study Phase: Phase 3
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
Enrollment Status: Terminated
Publish Date: May 28, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

2 Total Publications

The Impact of Social Determinants of Health, Namely Financial Assistance, on Overall Survival in Advanced-Stage Non-Small Cell Lung Cancer Patients.
The Impact of Social Determinants of Health, Namely Financial Assistance, on Overall Survival in Advanced-Stage Non-Small Cell Lung Cancer Patients.
Journal: Cureus
Published: March 19, 2023
Similar Doctors
Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (26.6 miles away)
813-692-4147
Languages Spoken:
English, Czech, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Lubomir Sokol is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Sokol is highly rated in 55 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sokol is currently accepting new patients.

Expertise in
42
conditions
Dr. Rami S. Komrokji
Hematology | Oncology
Expertise in
42
conditions
Dr. Rami S. Komrokji
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (26.6 miles away)
813-566-0119
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rami Komrokji is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Komrokji is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Sideroblastic Anemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Komrokji is currently accepting new patients.

Expertise in
20
conditions
Dr. Rachid C. Baz
Hematology | Oncology
Expertise in
20
conditions
Dr. Rachid C. Baz
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (26.6 miles away)
813-867-4646
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rachid Baz is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Baz is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Plasmacytoma, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Aspiration. Dr. Baz is currently accepting new patients.

Frequently Asked Questions about Dr. Neeharika S. Makani

How do I make an appointment with Dr. Neeharika S. Makani?

You can book an appointment with Dr. Neeharika S. Makani by calling their office at 727-344-6569. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Neeharika S. Makani a top-rated expert for Anemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Neeharika S. Makani is classified as an Distinguished expert for Anemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Neeharika S. Makani specialize in?

While Dr. Neeharika S. Makani is a Hematology, they have specific expertise in Anemia, Non-Small Cell Lung Cancer (NSCLC), and Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Neeharika S. Makani participate in research or clinical trials?

Yes. Dr. Neeharika S. Makani has published 2 articles and abstracts on conditions like Anemia. You can view a list of Dr. Neeharika S. Makani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Neeharika S. Makani accept my insurance?

Dr. Neeharika S. Makani accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 727-344-6569 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Makani's expertise for a condition
ConditionClose
    View All 28 Advanced Conditions
    View All 103 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile